MX390898B - Compuestos. - Google Patents
Compuestos.Info
- Publication number
- MX390898B MX390898B MX2019014332A MX2019014332A MX390898B MX 390898 B MX390898 B MX 390898B MX 2019014332 A MX2019014332 A MX 2019014332A MX 2019014332 A MX2019014332 A MX 2019014332A MX 390898 B MX390898 B MX 390898B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- tmlrcs
- tmlr
- lrcs
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona compuestos que son inhibidores alostéricos selectivos de mutantes de receptor del factor de crecimiento epidérmico (RFCE) que contienen TMLR, TMLCRS, LR, LRCS, su preparación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticamente activas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514244P | 2017-06-02 | 2017-06-02 | |
| EP17174334 | 2017-06-02 | ||
| US201762543438P | 2017-08-10 | 2017-08-10 | |
| PCT/EP2018/064399 WO2018220149A1 (en) | 2017-06-02 | 2018-06-01 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019014332A MX2019014332A (es) | 2022-03-24 |
| MX390898B true MX390898B (es) | 2025-03-21 |
Family
ID=62495802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014332A MX390898B (es) | 2017-06-02 | 2018-06-01 | Compuestos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11117890B2 (es) |
| EP (1) | EP3630754B8 (es) |
| JP (1) | JP7191045B2 (es) |
| KR (1) | KR20200015595A (es) |
| CN (1) | CN110753691B (es) |
| AU (1) | AU2018276441B2 (es) |
| BR (1) | BR112019025370A2 (es) |
| CA (1) | CA3065874A1 (es) |
| CL (1) | CL2019003501A1 (es) |
| CO (1) | CO2019013557A2 (es) |
| CR (1) | CR20190542A (es) |
| ES (1) | ES2927480T3 (es) |
| IL (1) | IL271013B2 (es) |
| MA (1) | MA48946A (es) |
| MX (1) | MX390898B (es) |
| MY (1) | MY201976A (es) |
| PE (1) | PE20200718A1 (es) |
| PH (1) | PH12019502662A1 (es) |
| PL (1) | PL3630754T3 (es) |
| TW (1) | TWI774780B (es) |
| UA (1) | UA126452C2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3986897T (lt) | 2019-06-21 | 2023-11-10 | F. Hoffmann-La Roche Ag | Egfr inhibitorius, skirtas vėžiui gydyti |
| WO2023116779A1 (zh) * | 2021-12-21 | 2023-06-29 | 上海艾力斯医药科技股份有限公司 | 一种联炔类化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| WO2008153760A1 (en) * | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009158369A1 (en) * | 2008-06-25 | 2009-12-30 | Schering Corporation | Synthesis and use of heterocyclic antibacterial agents |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN102093339B (zh) | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
| CN102060848B (zh) | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
| WO2013170774A1 (zh) * | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
| CN106687446B (zh) * | 2014-07-18 | 2020-04-28 | 百济神州(北京)生物科技有限公司 | 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途 |
| WO2016054987A1 (zh) * | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| MX2017014550A (es) * | 2015-05-14 | 2018-02-26 | Wistar Inst | Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan. |
| CA2987914C (en) | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
-
2018
- 2018-06-01 TW TW107118846A patent/TWI774780B/zh not_active IP Right Cessation
- 2018-06-01 UA UAA202000003A patent/UA126452C2/uk unknown
- 2018-06-01 MY MYPI2019007060A patent/MY201976A/en unknown
- 2018-06-01 ES ES18728875T patent/ES2927480T3/es active Active
- 2018-06-01 CN CN201880036589.7A patent/CN110753691B/zh active Active
- 2018-06-01 MX MX2019014332A patent/MX390898B/es unknown
- 2018-06-01 AU AU2018276441A patent/AU2018276441B2/en not_active Ceased
- 2018-06-01 JP JP2019566634A patent/JP7191045B2/ja active Active
- 2018-06-01 BR BR112019025370-0A patent/BR112019025370A2/pt not_active IP Right Cessation
- 2018-06-01 CR CR20190542A patent/CR20190542A/es unknown
- 2018-06-01 PE PE2019002464A patent/PE20200718A1/es unknown
- 2018-06-01 KR KR1020197038496A patent/KR20200015595A/ko not_active Ceased
- 2018-06-01 EP EP18728875.8A patent/EP3630754B8/en active Active
- 2018-06-01 CA CA3065874A patent/CA3065874A1/en active Pending
- 2018-06-01 PL PL18728875.8T patent/PL3630754T3/pl unknown
- 2018-06-01 MA MA048946A patent/MA48946A/fr unknown
-
2019
- 2019-11-25 PH PH12019502662A patent/PH12019502662A1/en unknown
- 2019-11-28 IL IL271013A patent/IL271013B2/en unknown
- 2019-11-29 CO CONC2019/0013557A patent/CO2019013557A2/es unknown
- 2019-11-29 CL CL2019003501A patent/CL2019003501A1/es unknown
- 2019-12-02 US US16/700,900 patent/US11117890B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630754A1 (en) | 2020-04-08 |
| IL271013B2 (en) | 2023-02-01 |
| CO2019013557A2 (es) | 2020-01-17 |
| CA3065874A1 (en) | 2018-12-06 |
| JP7191045B2 (ja) | 2022-12-16 |
| UA126452C2 (uk) | 2022-10-05 |
| AU2018276441A1 (en) | 2019-12-12 |
| JP2020524659A (ja) | 2020-08-20 |
| US20200102299A1 (en) | 2020-04-02 |
| RU2019143647A (ru) | 2021-07-09 |
| CN110753691B (zh) | 2024-02-02 |
| MA48946A (fr) | 2020-04-08 |
| KR20200015595A (ko) | 2020-02-12 |
| BR112019025370A2 (pt) | 2020-06-23 |
| PL3630754T3 (pl) | 2022-10-24 |
| CR20190542A (es) | 2020-01-14 |
| IL271013A (en) | 2020-01-30 |
| CL2019003501A1 (es) | 2020-06-05 |
| ES2927480T3 (es) | 2022-11-07 |
| AU2018276441B2 (en) | 2022-04-28 |
| MY201976A (en) | 2024-03-27 |
| US11117890B2 (en) | 2021-09-14 |
| EP3630754B8 (en) | 2022-08-31 |
| PE20200718A1 (es) | 2020-07-21 |
| CN110753691A (zh) | 2020-02-04 |
| PH12019502662A1 (en) | 2020-06-08 |
| TWI774780B (zh) | 2022-08-21 |
| RU2019143647A3 (es) | 2021-09-28 |
| MX2019014332A (es) | 2022-03-24 |
| EP3630754B1 (en) | 2022-07-27 |
| TW201902892A (zh) | 2019-01-16 |
| IL271013B (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020552154A1 (en) | Compounds | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| MX382339B (es) | Inhibidores g12c de kras. | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
| CY1122024T1 (el) | Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| EA201790650A1 (ru) | Лекарственная форма и способы применения абиратерона ацетата | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| EA201891586A1 (ru) | Антипролиферативные соединения и их фармацевтические композиции и применения | |
| JOP20190262B1 (ar) | مثبطات بيرازول magl | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| EA202090424A1 (ru) | Бициклические ингибиторы гистондеацетилазы | |
| MX2020008076A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| PH12019502662A1 (en) | Compounds | |
| EA201591480A1 (ru) | Способы лечения дискинезии и сопутствующих расстройств |